Use of oseltamivir in the treatment of canine parvoviral enteritis

Journal of Veterinary Emergency and Critical Care

Volumn 20, Issue 1, 2010, Pages 132-142

  Savigny, Michelle R ^a   Macintire, Douglass K ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Bacterial translocation; Diarrhea; Neuraminidase inhibitors

Indexed keywords

ANIMALIA; BACTERIA (MICROORGANISMS); CANIS FAMILIARIS;

ANTIVIRUS AGENT; OSELTAMIVIR;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; DRUG EFFECT; ENTERITIS; FELINE PANLEUKOPENIA VIRUS; FEMALE; LEUKOCYTE COUNT; MALE; MORTALITY; PARVOVIRUS INFECTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANIMALS; ANTIVIRAL AGENTS; DOG DISEASES; DOGS; ENTERITIS; FEMALE; LEUKOCYTE COUNT; MALE; OSELTAMIVIR; PARVOVIRIDAE INFECTIONS; PARVOVIRUS, CANINE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 77953464646     PISSN: 14793261     EISSN: 14764431     Source Type: Journal    
DOI: 10.1111/j.1476-4431.2009.00404.x     Document Type: Article

References (31)

1. Hoskins JD. Canine viral enteritis. Infectious Disease of the Dog and Cat 1998, 40-44. Greene CE. In, ed, 2nd ed, Philadelphia, WB Saunders, pp
2. Otto CM, Jackson CB, Rogell EJ. Recombinant bactericidal/permeability-increasing protein for treatment of parvovirus enteritis: a randomized, double-blinded, placebo-controlled trial. J Vet Intern Med 2001, 15:355-360.
3. Kariuki Njenga M, Nyaga PN, Buoro IBJ. Effectiveness of fluids and antibiotics as supportive therapy of canine parvovirus-2 enteritis in puppies. Bull Anim Health Prod Afr 1990, 38:379-389.
4. Glickman LT, Domanski LM, Patronek GJ. Breed-related risk factors for canine parvovirus enteritis. J Am Vet Med Assoc 1985, 187:589-594.
5. Macintire DK, Smith-Carr S. Canine parvovirus part II. Clinical signs, diagnosis, and treatment. Compend Contin Educ Pract Vet 1997, 19((3)):291-302.
6. Otto CM, Drobatz KJ, Soter C. Endotoxemia and tumor necrosis factor activity in dogs with naturally occurring parvoviral enteritis. J Vet Intern Med 1997, 11:65-70.
7. Mann FA, Boon GD, Wagner-Mann CC. Ionized and total magnesium concentrations in blood from dogs with naturally acquired parvoviral enteritis. J Am Vet Med Assoc 1998, 212:1398-1401.
8. Rewerts JM, McCaw DL, Cohn LA. Recombinant human granulocyte colony-stimulating factor for treatment of puppies with neutropenia secondary to canine parvovirus infection. J Am Vet Med Assoc 1998, 213:991-992.
9. Mischke R, Barth T, Wohlsein P. Effect of recombinant human granulocyte colony-stimulating factor on leukocyte count and survival rate of dogs with parvoviral enteritis. Res Vet Sci 2001, 70:221-225.
10. Mohr AJ, Leisewitz AL, Jacobson LS. Effect of early enteral nutrition on intestinal permeability, intestinal protein loss, and outcome in dogs with severe parvoviral enteritis. J Vet Intern Med 2003, 17:791-798.
11. Cohn LA, Rewerts JM, McCaw D. Plasma granulocyte colony stimulating factor concentrations in neutropenic, parvoviral enteritis-infected puppies. J Vet Intern Med 1999, 13:581-586.
12. Dimmitt R. Clinical experience with cross-protective antiendotoxin antiserum in dogs with parvoviral enteritis. Canine Pract 1991, 16:23-26.
13. De Mari K, Maynard L, Eun HM. Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled field trial. Vet Rec 2003, 152:105-108.
14. Martin V, Najbar W, Gueguen S. Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled challenge trial. Vet Microbiol 2002, 89:115-127.
15. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000, 335:827-835.
16. Ward P, Small I, Smith J. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005, 55((suppl 1)):i5-i21.
17. Hayden FG, Pavia AT. Antiviral management of seasonal and pandemic influenza. J Infect Dis 2006, 194((suppl 2)):S119-S126.
18. Kaiser L, Wat C, Mills T. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003, 163:1667-1672.
19. McCuller JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 2003, 187:1000-1009.
20. McCullers JA. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis 2004, 190:519-526.
21. Peltola VT, Murti KG, McCullers JA. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J Infect Dis 2005, 192:249-257.
22. Bhatia A, Kast RE. How influenza's neuraminidase promotes virulence and creates localized lung mucosa immunodeficiency. Cell Mol Biol Lett 2007, 12:111-119.
23. Matheson NJ, Harden AR, Perera R. Neuraminidase inhibitors for preventing and treating influenza in children (review). Cochrane Lib 2007, 1:1-40.
24. Turk J, Miller M, Brown T. Coliform septicemia and pulmonary disease associated with canine parvoviral enteritis: 88 cases (1987-1988). J Am Vet Med Assoc 1990, 196:771-773.
25. Mantione NL, Otto CM. Characterization of the use of antiemetic agents in dogs with parvoviral enteritis treated at a veterinary teaching hospital: 77 cases (1997-2000). J Am Vet Med Assoc 2005, 227:1787-1793.
26. Gillissen A, Hoffken G. Early therapy with the neuraminidase inhibitor oseltamivir maximizes its efficacy in influenza treatment. Med Microbiol Immunol 2002, 191:165-168.
27. Oo C, Snell P, Barrett J. Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules. Int J Pharm 2003, 257:297-299.
28. Li W, Escarpe PA, Eisenberg EJ. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998, 42:647-653.
29. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999, 37:471-484.
30. Gatt M, Reddy BS, Macfie J. Review article: bacterial translocation in the critically ill - evidence and methods of prevention. Aliment Pharmacol Ther 2007, 25:741-757.
31. http://www.who.int/csr/disease/influenza/oseltamivir_faqs/en/index.html, World Health Organization., WHO/ECDC frequently asked questions for oseltamivir resistance [document on the internet]. WHO; Feb 15, 2008. Available at, Accessed Feb 15, 2009